A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Condition(s):Relapsed or Refractory Follicular LymphomaLast Updated:March 15, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed or Refractory Follicular LymphomaLast Updated:March 15, 2024Not yet recruiting
Condition(s):Relapsed/Refractory Follicular Lymphoma With EZH2Last Updated:September 30, 2022Recruiting
Condition(s):Relapsed/Refractory Follicular LymphomaLast Updated:February 28, 2024Recruiting
Condition(s):Relapsed Follicular Lymphoma; Refractory Follicular LymphomaLast Updated:October 23, 2023Terminated
Condition(s):Relapsed / Refractory Follicular LymphomaLast Updated:July 1, 2020Unknown status
Condition(s):Follicular Lymphoma; Refractory Follicular LymphomaLast Updated:March 7, 2024Not yet recruiting
Condition(s):Follicular Lymphoma; Relapsed and Refractory Follicular LymphomaLast Updated:March 24, 2022Unknown status
Condition(s):Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular LymphomaLast Updated:February 15, 2024Recruiting
Condition(s):Lymphoma, FollicularLast Updated:December 18, 2023Recruiting
Condition(s):Relapsed Follicular Lymphoma; Refractory Follicular LymphomaLast Updated:July 7, 2023Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.